Critical issues in patient selection, efficacy, and safety of renal denervation

Hypertension

Volumn 63, Issue 3, 2014, Pages 426-432

  Schlaich, Markus P ^a   Esler, Murray D ^a   Fink, Greg D ^b   Osborn, John W ^c   Euler, David E ^d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC SYSTEM; ANIMAL; BLOOD PRESSURE; DENERVATION; HUMAN; HYPERTENSION; INNERVATION; KIDNEY; METHODOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; REVIEW; TREATMENT OUTCOME;

ANIMALS; BLOOD PRESSURE; DENERVATION; HUMANS; HYPERTENSION; KIDNEY; PATIENT SELECTION; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84894412283     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02144     Document Type: Review

References (48)

1. Esler M. The 2009 Carl Ludwig lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: The transition from mechanisms to medical management. J Appl Physiol (1985). 2010;108:227-237.
2. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75-197.
3. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-934.
4. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152:1501-1504.
5. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-1281.
6. Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: Ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012;60:596-606.
7. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71:659-682.
8. Smits JF, Brody MJ. Activation of afferent renal nerves by intrarenal bradykinin in conscious rats. Am J Physiol. 1984;247(6 Pt 2):R1003-R1008.
9. Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens. 1984;2:349-359.
10. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25(4 Pt 2):878-882.
11. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61:457-464.
12. Hering D, Lambert E, Marusic P, Walton A, Krum H, Lambert G, Esler M, Schlaich M. Sustained blood pressure reduction and sympathetic inhibition one year after renal denervation in patients with resistant hypertension. J Hypertens.2013;31: E-Supplement A, e104.
13. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficultto-control hypertensive patients: Prospective case series. Hypertension. 2012;60:1485-1490.
14. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-917.
15. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Boddddhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet. 2010;376:1903-1909.
16. Esler MD, Krum H, Schlaich M, Schmieder RE, Boddddhm M, Sobotka PA; Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: One-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:2976-2982.
17. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPLICITY HTN-3 trial. Clin Cardiol. 2012;35:528-535.
18. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-e526.
19. Mancia G, De Backer G, Dominiczak A, et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751-1762.
20. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-1080.
21. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898-902.
22. Pimenta E, Calhoun DA. Resistant hypertension: Incidence, prevalence, and prognosis. Circulation. 2012;125:1594-1596.
23. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C. ESH position paper: Renal denervation-An interventional therapy of resistant hypertension. J Hypertens. 2012;30:837-841.
24. Mahfoud F, Lüscher TF, Andersson B, et al.; European Society of Cardiology. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149-2157.
25. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132-140.
26. Zuern CS, Eick C, Rizas KD, Bauer S, Langer H, Gawaz M, Bauer A. Impaired cardiac baroreflex sensitivity predicts response to renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2013. In press.
27. Kaltenbach B, Franke J, Bertog SC, Steinberg DH, Hofmann I, Sievert H. Renal sympathetic denervation as second-line therapy in mild resistant hypertension: A pilot study. Catheter Cardiovasc Interv. 2013;81:335-339.
28. Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, Spies A, Ukena C, Laufs U, Uder M, Boddddhm M, Schmieder RE. Renal denervation in moderate treatment resistant hypertension. J Am Coll Cardiol. 2013; 62:1880-1886.
29. Rippy MK, Zarins D, Barman NC, Wu A, Duncan KL, Zarins CK. Catheter-based renal sympathetic denervation: Chronic preclinical evidence for renal artery safety. Clin Res Cardiol. 2011;100:1095-1101.
30. Steigerwald K, Titova A, Malle C, Kennerknecht E, Jilek C, Hausleiter J, Nährig JM, Laugwitz KL, Joner M. Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model. J Hypertens. 2012;30:2230-2239.
31. Templin C, Jaguszewski M, Ghadri JR, Sudano I, Gaehwiler R, Hellermann JP, Schoenenberger-Berzins R, Landmesser U, Erne P, Noll G, Lüscher TF. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: Pre-And post-procedural comparison with the Simplicity catheter system and the EnligHTN multi-electrode renal denervation catheter. Eur Heart J. 2013; 34:2141-8, 2148b.
32. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012;380:778.
33. Kaltenbach B, Id D, Franke JC, Sievert H, Hennersdorf M, Maier J, Bertog SC. Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol. 2012;60:2694-2695.
34. Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419-424.
35. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Boddddhm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250-1257.
36. Ukena C, Mahfoud F, Kindermann I, Barth C, Lenski M, Kindermann M, Brandt MC, Hoppe UC, Krum H, Esler M, Sobotka PA, Boddddhm M. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2011;58:1176-1182.
37. Mahfoud F, Lenski M, Ukena C, Barth C, Razouk A, Fischer D, Laufs U, Kindermann I, Boddddhm M. Influence of renal sympathetic denervation on orthostatic function in patients with resistant hypertension. Circulation. 2012;126:A17201.
38. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: The EnligHTN I trial. Eur Heart J. 2013;34:2132-2140.
39. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: A meta-Analysis. J Hypertens. 2004;22:435-445.
40. Schmieder RE, Ruilope LM, Ott C, Mahfoud F, Boddddhm M. Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. J Hum Hypertens. 2013. In press.
41. Dinenno FA, Jones PP, Seals DR, Tanaka H. Age-Associated arterial wall thickening is related to elevations in sympathetic activity in healthy humans. Am J Physiol Heart Circ Physiol. 2000;278:H1205-H1210.
42. Brandt MC, Reda S, Mahfoud F, Lenski M, Boddddhm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol. 2012;60:1956-1965.
43. Hering D, Lambert EA, Marusic P, Ika-Sari C, Walton AS, Krum H, Sobotka PA, Mahfoud F, Boddddhm M, Lambert GW, Esler MD, Schlaich MP. Renal nerve ablation reduces augmentation index in patients with resistant hypertension. J Hypertens. 2013;31:1893-1900.
44. Krum H, Schlaich MP, Boddddhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatmentresistant hypertension: Final 3-year report of the Symplicity HTN-1 study. Lancet. 2013; in press.
45. Kline RL, Mercer PF. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am J Physiol. 1980;238:R353-R358.
46. Mulder J, Hoddddkfelt T, Knuepfer MM, Kopp UC. Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats. Am J Physiol Regul Integr Comp Physiol. 2013;304:R675-R682.
47. Shannon JL, Headland R, MacIver AG, Ferryman SR, Barber PC, Howie AJ. Studies on the innervation of human renal allografts. J Pathol. 1998;186:109-115.
48. Hansen JM, Abildgaard U, Fogh-Andersen N, Kanstrup IL, Bratholm P, Plum I, Strandgaard S. The transplanted human kidney does not achieve functional reinnervation. Clin Sci (Lond). 1994;87:13-20.